BNC lands cancer drug formulation contract

- Last updated on GMT

Bio Nano Consulting (BNC) says University of London School of Pharmacy deal helped land first Ph I trial formulation services contract.

The UK firm, a nanotechnology partnering focused JV between the University of London School of Pharmacy and Imperial College London, will mange development of an orally-available formulation of a candidate cancer treatment for an undisclosed US biotech developer.

The proof-of-concept project, which will be conducted by researchers at the School of Pharmacy, follows signing of a service level agreement (SLA) with the institution and extends the scope of BNC’s trial support expertise according to CEO David Sarphie.

The SLA significantly expands our established pool of world class scientist that we manage and draw upon for specific life science projects, including cancer research​.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars